TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+30.6%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$226M
AUM Growth
+$226M
(-35%)
Cap. Flow
-$134M
Cap. Flow
% of AUM
-59.23%
Top 10 Holdings %
Top 10 Hldgs %
63.82%
Holding
91
New
48
Increased
7
Reduced
10
Closed
22
Top Buys
| 1 |
West Pharmaceutical
WST
|
$22.8M |
| 2 |
Axsome Therapeutics
AXSM
|
$15.4M |
| 3 |
Merck
MRK
|
$14.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$12.9M |
| 5 |
Ascendis Pharma
ASND
|
$12.1M |
Top Sells
| 1 |
Biogen
BIIB
|
$24.2M |
| 2 |
argenx
ARGX
|
$23.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$20.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$20.7M |
| 5 |
Eli Lilly
LLY
|
$18.5M |
Sector Composition
| 1 | Healthcare | 99.28% |
| 2 | Real Estate | 0.33% |
| 3 | Industrials | 0.11% |
| 4 | Financials | 0.11% |
| 5 | Energy | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
West Pharmaceutical
WST
$17.8B
| $22.8M | 9.24% | +97,084 | New | +$22.8M |
|
|
2
Eli Lilly
LLY
$657B
| $19.9M | 8.06% | 54,469 -50,701 | -48% | -$18.5M |
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $15.5M | 6.27% | 119,695 +24,250 | +25% | +$3.14M |
|
|
4
Axsome Therapeutics
AXSM
$6.05B
| $15.4M | 6.24% | +200,054 | New | +$15.4M |
|
|
5
Merck
MRK
$210B
| $14.1M | 5.7% | +126,912 | New | +$14.1M |
|
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.9M | 5.23% | +124,979 | New | +$12.9M |
|
|
7
Ascendis Pharma
ASND
$11.8B
| $12.1M | 4.9% | +99,215 | New | +$12.1M |
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $11.5M | 4.64% | +221,897 | New | +$11.5M |
|
9
Stevanato
STVN
$6.28B
| $10.3M | 4.17% | 574,037 -197,896 | -26% | -$3.56M |
|
10
Astria Therapeutics
ATXS
$349M
| $9.7M | 3.92% | 651,330 +19,751 | +3% | +$294K |
|
11
Celldex Therapeutics
CLDX
$1.47B
| $7.85M | 3.17% | 176,109 -62,460 | -26% | -$2.78M |
|
12
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.66M | 3.1% | +26,386 | New | +$7.66M |
|
13
Akero Therapeutics
AKRO
$3.74B
| $7.06M | 2.86% | 128,851 -80,397 | -38% | -$4.41M |
|
14
Vaxcyte
PCVX
$4B
| $5.44M | 2.2% | 113,477 +34,066 | +43% | +$1.63M |
|
|
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.37M | 2.17% | +141,466 | New | +$5.37M |
|
16
Altimmune
ALT
$338M
| $5.36M | 2.17% | 325,694 +168,391 | +107% | +$2.77M |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.2M | 2.1% | 243,079 +52,482 | +28% | +$1.12M |
|
|
AVDL
18
Avadel Pharmaceuticals
AVDL
$1.43B
| $4.9M | 1.98% | +684,556 | New | +$4.9M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.74M | 1.92% | 104,598 -46,936 | -31% | -$2.13M |
|
20
InMode
INMD
$944M
| $4.54M | 1.84% | +127,242 | New | +$4.54M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $3.68M | 1.49% | 93,364 -40,967 | -30% | -$1.62M |
|
22
X4 Pharmaceuticals
XFOR
$84.2M
| $3.68M | 1.49% | 3,706,517 +1,202,511 | +48% | +$1.19M |
|
23
Guardant Health
GH
$8.41B
| $3.55M | 1.44% | 130,448 -155,500 | -54% | -$4.23M |
|
24
TG Therapeutics
TGTX
$4.65B
| $3.41M | 1.38% | +288,462 | New | +$3.41M |
|
25
Kezar Life Sciences
KZR
$28.9M
| $3.33M | 1.35% | 473,544 -236,189 | -33% | -$1.66M |
|